Contents
This article presents a cost-effectiveness analysis comparing sentinel lymph node (SLN) biopsy with lymphadenectomy in the surgical staging of patients with intermediate- and high-risk endometrial carcinoma. The study utilized data from 829 patients and found that the implementation of the SLN algorithm, primarily through robotic surgery, led to improved health outcomes and reduced costs compared to lymphadenectomy. Over a 10-year period, SLN biopsy resulted in better quality-adjusted life years (QALYs) and cost savings of $1,051 per patient. Sensitivity analyses confirmed the robustness of these results. The study concluded that SLN biopsy is a more cost-effective strategy than lymphadenectomy, providing better health outcomes at lower costs, especially when using robotic surgery. The findings support the wider adoption of SLN biopsy for staging in this patient population.
Citation
Bjerre Trent P, Eriksson AG, Staff AC, Juul-Hansen KE, Burger EA, Wangen KR. A cost-effectiveness analysis of sentinel lymph node biopsy compared with lymphadenectomy in intermediate- and high-risk endometrial carcinoma. Int J Gynecol Cancer. 2024 Oct 21:ijgc-2024-005906.
Link
https://ijgc.bmj.com/content/early/2024/10/21/ijgc-2024-005906.long
No comments
You can write comments after you log in.